Background: We conducted a single-arm clinical trial in institutionalized seniors, on the effects of high-dose vitamin D3-fortified bread daily intake (clinicaltrials.gov registration NCT00789503).
Background
Older adults are particularly susceptible to vitamin D insufficiency [1] particularly in nursing homes [2] . In Romania, serum 25-hydroxyvitamin D (25(OH)D) concentrations in institutionalized seniors were 28.5 ± 10.8 nmol/L [3] , far below the minimum 50 nmol/L that the US Institutes of Medicine has set as the basis for its latest recommended dietary allowance (RDA) [4] .
The serum 25(OH)D concentrations likely required to minimize the risk of falls and fractures has been estimated to be between 75 and 100 nmol/l [5] . We previously provided evidence to support this recommendation by completing a single-arm clinical trial in which we provided institutionalized seniors with bread fortified each day with 125 μg (5,000 IU) of vitamin D 3 [3] . This dietary protocol ensured that virtually all of the adults achieved serum 25 (OH)D concentrations of at least 75 nmol/L. Here we report the long-term follow-up of study subjects at 1 and 3 years after discontinuing the clinical trial. During this time, the subjects have returned to their previous standard of health care, which did not provide a vitamin D supplement.
Subjects and methods

Study population and design
The single-arm clinical trial (clinicaltrials.gov registration NCT00789503) initially enrolled 45 patients (28 women and 17 men), 58 to 89 years of age (71 ± 6.9 years), all residing in a nursing home located in Iasi, Romania (Latitude 47°N) [3] . At the end of the one-year supplementation protocol (consumption of bread buns fortified with 5,000 IU vitamin D 3 per daily serving) [3] , 33 patients were assessed by Dual-energy X-ray absorptiometry (DXA) (January 2005). Initial and final bone mineral density (BMD) data were available for 33 subjects. These patients were retested by DXA one and three years after the vitamin D protocol was discontinued (January 2006 and January 2008, respectively).
Study protocol
In the original study, all subjects received 125 μg (5,000 IU) vitamin D 3 /day and 800 mg calcium carbonate/day (320 mg of elemental calcium) for 1 yr.
Bone mineral density (BMD) of the lumbar spine and proximal femur was measured at baseline and after 12 months of vitamin D 3 supplementation [3] . The BMD measurements at the end of vitamin D 3 supplementation were taken as the baseline values for this follow-up report (i.e. "baseline" refers to measures obtained at the end of 1 yr of vitamin D), and additional measurements were obtained after 12 and 36 months of follow-up study. Blood for serum calcium, 25(OH)D and serum PTH was obtained at baseline and at 1 and 3 years follow-up.
At the beginning of the original study, the 10-day food records obtained from the nursing home showed that the per-day vitamin D intake was 84 IU, while calcium intake was 717 mg. The participants did not take supplements of calcium, vitamin D, or both in the preceding 36 mo.
Both the intervention and follow-up studies were approved by the Human Investigation Review Committee at Grigore T. Popa University, and written informed consent was obtained from each subject.
Blood collection and analytical methods
Fasting blood samples were collected at baseline and after 1 and 3 years of follow-up study. Serum and plasma were kept frozen until analysis.
Serum calcium concentrations were measured by standard laboratory methods. Serum 25(OH)D concentrations were assayed by HPLC method [6] (results were validated through the DEQAS proficiency survey (www.deqas.org) for 25(OH)D, and the results were within the all-laboratory methods mean). Serum intact PTH was measured by an enzyme-amplified "two-step" sandwich-type immunoassay (DSL, Webster, Texas, USA) with an inter-assay CV ranging from 6.0 to 6.3% (normal range for adults 40-70 years of age, pg/ml). The BMD of the lumbar spine, femoral neck and trochanter were measured by dual energy x-ray absorbtiometry (Hologic, Delfi A and Delfi W). The calibration of bone densitometer was performed by scanning the European Spine Phantom. All measurements were performed by the same experienced technician.
Statistical analysis
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc, Chicago). Data are expressed as mean ± SD. The distributions of all variables were tested with Kolmogorov-Smirnov tests. Descriptive statistics (mean and SD) were determined for all variables. Effects of the follow-up after the vitamin D protocol was completed were examined using the paired t-test versus the "baseline" values for each subject, which in the context of the present follow-up report are those values obtained at the end of the 1-yr intervention with vitamin Dfortified bread. A two-way repeated-measures ANOVA was conducted to explore the impact of sex and age on outcome variables (lumbar and hip BMD, concentrations of serum calcium, 25(OH)D, and PTH).
Results
Characteristics of the population
Thirty-three older nursing home residents were included into the follow-up study, which represents the population of participants having completed the Vitamin D fortified bread intervention. Baseline characteristics of the patients are shown in Table 1 . Two patients withdrew from the study before the 12 month-follow-up visit. One 
Measurements of serum calcium and PTH
There were no significant differences in serum calcium concentrations at baseline versus 12 and 36 month followup (Table 2 ). Compared to the end-of clinical trial, PTH concentrations significantly increased by 12 months of follow-up (p = 0.0001) and by 36 months (p = 0.0001) but remained within the reference range. No treatment-related adverse events were observed during follow-up.
Bone mineral density measurements
Upon withdrawal of vitamin D 3 (125 μg) supplementation, there were no significant differences in the mean percentages of change in lumbar spine; the mean percentages of change from baseline in lumbar spine BMD at 1-year follow-up was -0.31% and at 3-year follow-up was 1.03%. Statistically significant changes from baseline were noticed in hip BMD (Table 2) ; the mean relative change from baseline in hip BMD at 1-year follow-up was -1.52% and at 3-year follow-up was -1.99%.
Discussion
Corrective action was not implemented after the original clinical trial was completed because the study subjects returned to their standard of care. Until the end of this follow-up, there was no compelling reason to provide more vitamin D. Although it was reassuring that at follow-up Year 1, the serum 25(OH)D was appropriate for the group, the data at follow-up Year 3 show that 25 (OH)D had not established its new plateau. Previous studies suggests that when vitamin D supplementation is stopped, the serum 25(OH)D concentrations exhibit an apparent half-life of two months [7] . However, the de- after discontinuation, but serum 25(OH)D concentrations were not reported [8] .
The present report is to our knowledge the longest follow-up after discontinuation of vitamin D, and it does show a sustained biochemical benefit to the one-year point, in that the serum 25(OH)D exceeded 50 nmol/L. However, by follow-up Year 3, the benefits of vitamin D fortification, were essentially gone. At follow-up Year 1, PTH had increased significantly from the end-of-vitamin D baseline. At follow-up Year 3, there was evidence that bone loss had progressed at the hip, but since there was no reference group in this study, the bone loss may reflect the normal age-related decline. The strength of this study is in its 3-yr characterization of the progression of the decline in 25(OH)D in older adults who had beforehand, received enough vitamin D to achieve 25(OH)D concentrations that most would consider to be in the optimal range. Among the weaknesses of this work is the lack of a reference group against which to compare the variables studied.
Conclusions
In retrospect, it is unfortunate that the serum 25(OH)D concentrations eventually returned to the osteomalacic levels present before the subjects initially entered the breadfortification clinical trial. Lessons learned here are, firstly, that vitamin D nutritional status exhibits a long half-life in the body, whereby follow-up testing even at 1 year after a change in dose may not reflect a true plateau (i.e. steadystate) value; and secondly, that when a need for nutrient is established, even if this recognition is as part of a research protocol, then the appropriate action is to institute corrective measures beyond the extent of the research protocol. 
